vs
Side-by-side financial comparison of Bone Biologics Corp (BBLG) and Century Therapeutics, Inc. (IPSC). Click either name above to swap in a different company.
Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.
Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics. Bristol Myers Squibb acquired the company in January 2024.
BBLG vs IPSC — Head-to-Head
Income Statement — Q1 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $255 | $0 |
| Net Profit | $-866.0K | $-19.2M |
| Gross Margin | — | — |
| Operating Margin | -354327.8% | — |
| Net Margin | -339596.1% | — |
| Revenue YoY | -54.1% | — |
| Net Profit YoY | 76.7% | 46.8% |
| EPS (diluted) | $-1.31 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $109.2M | ||
| Q1 24 | $255 | — | ||
| Q4 23 | $348 | — | ||
| Q3 23 | $536 | — | ||
| Q2 23 | $428 | — |
| Q4 25 | — | $-19.2M | ||
| Q3 25 | — | $-34.4M | ||
| Q2 25 | — | $-32.5M | ||
| Q1 25 | — | $76.6M | ||
| Q1 24 | $-866.0K | — | ||
| Q4 23 | $-1.5M | — | ||
| Q3 23 | $-1.9M | — | ||
| Q2 23 | $-1.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 67.9% | ||
| Q1 24 | -354327.8% | — | ||
| Q4 23 | -333335.6% | — | ||
| Q3 23 | -388225.7% | — | ||
| Q2 23 | -710249.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 70.1% | ||
| Q1 24 | -339596.1% | — | ||
| Q4 23 | -445369.3% | — | ||
| Q3 23 | -358154.7% | — | ||
| Q2 23 | -413373.4% | — |
| Q4 25 | — | $-0.25 | ||
| Q3 25 | — | $-0.40 | ||
| Q2 25 | — | $-0.38 | ||
| Q1 25 | — | $0.89 | ||
| Q1 24 | $-1.31 | — | ||
| Q4 23 | $31.30 | — | ||
| Q3 23 | $-4.90 | — | ||
| Q2 23 | $-5.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $117.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7M | $158.9M |
| Total Assets | $3.8M | $223.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $117.1M | ||
| Q3 25 | — | $132.7M | ||
| Q2 25 | — | $155.8M | ||
| Q1 25 | — | $165.1M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | $158.9M | ||
| Q3 25 | — | $176.3M | ||
| Q2 25 | — | $209.9M | ||
| Q1 25 | — | $240.4M | ||
| Q1 24 | $3.7M | — | ||
| Q4 23 | $2.9M | — | ||
| Q3 23 | $3.8M | — | ||
| Q2 23 | $5.7M | — |
| Q4 25 | — | $223.7M | ||
| Q3 25 | — | $244.7M | ||
| Q2 25 | — | $284.7M | ||
| Q1 25 | — | $315.6M | ||
| Q1 24 | $3.8M | — | ||
| Q4 23 | $3.7M | — | ||
| Q3 23 | $5.0M | — | ||
| Q2 23 | $7.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $-16.1M |
| Free Cash FlowOCF − Capex | — | $-16.2M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-16.1M | ||
| Q3 25 | — | $-25.6M | ||
| Q2 25 | — | $-27.6M | ||
| Q1 25 | — | $-34.6M | ||
| Q1 24 | $-1.3M | — | ||
| Q4 23 | $-2.0M | — | ||
| Q3 23 | $-2.6M | — | ||
| Q2 23 | $-3.6M | — |
| Q4 25 | — | $-16.2M | ||
| Q3 25 | — | $-25.8M | ||
| Q2 25 | — | $-27.9M | ||
| Q1 25 | — | $-35.1M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -32.2% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.4% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.45× | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
